Literature DB >> 12390408

Mixed microbial aetiology of community-acquired pneumonia in children.

Matti Korppi1.   

Abstract

Seven paediatric studies on community-acquired pneumonia with serological methods for both viruses and bacteria have been published, allowing the evaluation of concomitant multiple etiological findings. In these studies, dual viral infection has been present in 0-14%, dual bacterial infection likewise in 0-14%, and mixed viral-bacterial infection in 3-30% of the pneumonia cases. The results confirm former clinical observations that respiratory viruses often pave the way for airway-colonising bacteria. The measured frequency of multiple infections has been dependent on the available test panel, mainly on the tests used for pneumococcal aetiology. Mixed viral-bacterial infections have been especially common in young children under 2 years of age, reflecting the high frequency of respiratory syncytial virus infections and their tendency to induce bacterial co-infections. No microbe-specific viral-bacterial associations have been demonstrated. The clinical implications of mixed viral-bacterial infections, compared with viral infections alone or bacterial infections alone, have so far remained unresolved. Current guidelines recommend antibiotic therapy for all community-acquired pneumonia cases in children.

Entities:  

Mesh:

Year:  2002        PMID: 12390408     DOI: 10.1034/j.1600-0463.2002.11007801.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  19 in total

1.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

Review 2.  Short-course therapy for community-acquired pneumonia in paediatric patients.

Authors:  Shamim Qazi
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Community-acquired pneumonia in children: issues in optimizing antibacterial treatment.

Authors:  Matti Korppi
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

4.  Difference of clinical features in childhood Mycoplasma pneumoniae pneumonia.

Authors:  You-Sook Youn; Kyung-Yil Lee; Ja-Young Hwang; Jung-Woo Rhim; Jin-Han Kang; Joon-Sung Lee; Ji-Chang Kim
Journal:  BMC Pediatr       Date:  2010-07-06       Impact factor: 2.125

5.  Prediction of delayed recovery from pediatric community-acquired pneumonia.

Authors:  Massimiliano Don; Francesca Valent; Mario Canciani; Matti Korppi
Journal:  Ital J Pediatr       Date:  2010-07-29       Impact factor: 2.638

Review 6.  Pneumococcal serology in children's respiratory infections.

Authors:  M Korppi; M Leinonen; O Ruuskanen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-12-18       Impact factor: 3.267

7.  Detection of viral and bacterial pathogens in hospitalized children with acute respiratory illnesses, Chongqing, 2009-2013.

Authors:  Lan Wei; Wei Liu; Xiao-Ai Zhang; En-Mei Liu; Yin Wo; Benjamin J Cowling; Wu-Chun Cao
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

8.  The significance of chest ultrasound and chest X-ray in the diagnosis of children clinically suspected of pneumonia.

Authors:  M B Rahmati; M Ahmadi; S Hasanpur; S H Zare; M Jafari
Journal:  J Med Life       Date:  2015

9.  Poly I:C enhances susceptibility to secondary pulmonary infections by gram-positive bacteria.

Authors:  Xiaoli Tian; Feng Xu; Wing Yi Lung; Cherise Meyerson; Amir Ali Ghaffari; Genhong Cheng; Jane C Deng
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

10.  Adenovirus species C is associated with chronic suppurative lung diseases in children.

Authors:  Danielle F Wurzel; Ian M Mackay; Julie M Marchant; Claire Y T Wang; Stephanie T Yerkovich; John W Upham; Heidi C Smith-Vaughan; Helen L Petsky; Anne B Chang
Journal:  Clin Infect Dis       Date:  2014-04-18       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.